268 related articles for article (PubMed ID: 24237224)
1. Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.
Leuci V; Mesiano G; Gammaitoni L; Todorovic M; Giraudo L; Carnevale-Schianca F; Aglietta M; Sangiolo D
Anticancer Agents Med Chem; 2014 Feb; 14(2):211-22. PubMed ID: 24237224
[TBL] [Abstract][Full Text] [Related]
2. Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies.
Schmeel FC; Schmeel LC; Gast SM; Schmidt-Wolf IG
Int J Mol Sci; 2014 Aug; 15(8):14632-48. PubMed ID: 25196601
[TBL] [Abstract][Full Text] [Related]
3. Use of allogeneic NK cells for cancer immunotherapy.
Geller MA; Miller JS
Immunotherapy; 2011 Dec; 3(12):1445-59. PubMed ID: 22091681
[TBL] [Abstract][Full Text] [Related]
4. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.
Zakrzewski JL; Suh D; Markley JC; Smith OM; King C; Goldberg GL; Jenq R; Holland AM; Grubin J; Cabrera-Perez J; Brentjens RJ; Lu SX; Rizzuto G; Sant'Angelo DB; Riviere I; Sadelain M; Heller G; Zúñiga-Pflücker JC; Lu C; van den Brink MR
Nat Biotechnol; 2008 Apr; 26(4):453-61. PubMed ID: 18376399
[TBL] [Abstract][Full Text] [Related]
5. Cytokine-induced killer cells hunt individual cancer cells in droves in a mouse model.
Kim JS; Kim YG; Lee HK; Park EJ; Kim B; Kang JS; Lee H; Kim Y; Hong JT; Han SB
Cancer Immunol Immunother; 2017 Feb; 66(2):193-202. PubMed ID: 27888293
[TBL] [Abstract][Full Text] [Related]
6. Adoptive cell immunotherapy for breast cancer: harnessing the power of immune cells.
Li X; Zhu Y; Yi J; Deng Y; Lei B; Ren H
J Leukoc Biol; 2024 Apr; 115(5):866-881. PubMed ID: 37949484
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cells, ageing and cancer.
Naumova E; Pawelec G; Mihaylova A
Cancer Immunol Immunother; 2016 Apr; 65(4):367-70. PubMed ID: 26969613
[TBL] [Abstract][Full Text] [Related]
8. Analysis of HLA expression in human tumor tissues.
Cabrera T; López-Nevot MA; Gaforio JJ; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2003 Jan; 52(1):1-9. PubMed ID: 12536234
[TBL] [Abstract][Full Text] [Related]
9. Tumour cell resistance to non-MHC-restricted lymphocytes: molecular mechanisms and clinical implications.
Tagliaferri P; Guarrasi R; Caraglia M; Morelli D; Fabbrocini A; Correale P; Bianco AR
Cancer Immunol Immunother; 1998 May; 46(3):121-7. PubMed ID: 9625535
[No Abstract] [Full Text] [Related]
10. PBRM1 and the glycosylphosphatidylinositol biosynthetic pathway promote tumor killing mediated by MHC-unrestricted cytotoxic lymphocytes.
Menasche BL; Davis EM; Wang S; Ouyang Y; Li S; Yu H; Shen J
Sci Adv; 2020 Nov; 6(48):. PubMed ID: 33246952
[TBL] [Abstract][Full Text] [Related]
11. Current Developments in the Preclinical and Clinical use of Natural Killer T cells.
Kratzmeier C; Singh S; Asiedu EB; Webb TJ
BioDrugs; 2023 Jan; 37(1):57-71. PubMed ID: 36525216
[TBL] [Abstract][Full Text] [Related]
12. Complete remission of cancer in late-stage disease by radiation and transfer of allogeneic MHC-matched immune T cells: lessons from GvL studies in animals.
Schirrmacher V
Cancer Immunol Immunother; 2014 Jun; 63(6):535-43. PubMed ID: 24610041
[TBL] [Abstract][Full Text] [Related]
13. MHC tetramer technology: Exploring T cell biology in health and disease.
Tiwari R; Singh VK; Rajneesh ; Kumar A; Gautam V; Kumar R
Adv Protein Chem Struct Biol; 2024; 140():327-345. PubMed ID: 38762273
[TBL] [Abstract][Full Text] [Related]
14. Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor.
Srivastava N; Srivastava PK
PLoS One; 2009 Jul; 4(7):e6094. PubMed ID: 19593447
[TBL] [Abstract][Full Text] [Related]
15. Tumorigenesis and anti-tumor immune responses in Xenopus.
Goyos A; Robert J
Front Biosci (Landmark Ed); 2009 Jan; 14(1):167-76. PubMed ID: 19273061
[TBL] [Abstract][Full Text] [Related]
16. Mutations and regulatory anomalies effecting tumor cell immune functions.
Blanck G
Cancer Immunol Immunother; 2004 Jan; 53(1):1-16. PubMed ID: 13680191
[TBL] [Abstract][Full Text] [Related]
17. Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.
Zakrzewski JL; Suh D; Markley JC; Smith OM; King C; Goldberg GL; Jenq R; Holland AM; Grubin J; Cabrera-Perez J; Brentjens RJ; Lu SX; Rizzuto G; Sant'Angelo DB; Riviere I; Sadelain M; Heller G; Zúñiga-Pflücker JC; Lu C; van den Brink MRM
Nat Biotechnol; 2024 Apr; 42(4):674. PubMed ID: 38531977
[No Abstract] [Full Text] [Related]
18. [Bilateral breast cancer: risk factors, prognostic factors and patient monitoring].
Hot'ko IeS; TSygyka DĬ; Rohach IM; ZHero SV; Pohorielova NIe; Pryhara DV; Hot'ko IIu; Ihnatko VIa
Wiad Lek; 2014; 67(2 Pt 2):180-3. PubMed ID: 25796820
[TBL] [Abstract][Full Text] [Related]
19. Drugs for ADHD.
Med Lett Drugs Ther; 2015 Mar; 57(1464):37-40. PubMed ID: 25758544
[No Abstract] [Full Text] [Related]
20. Relationship of cigarette smoking with inflammation and subclinical vascular disease: the Multi-Ethnic Study of Atherosclerosis.
McEvoy JW; Nasir K; DeFilippis AP; Lima JA; Bluemke DA; Hundley WG; Barr RG; Budoff MJ; Szklo M; Navas-Acien A; Polak JF; Blumenthal RS; Post WS; Blaha MJ
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):1002-10. PubMed ID: 25745060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
